KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Share-based Compensation (2018 - 2025)

Historic Share-based Compensation for Amneal Pharmaceuticals (AMRX) over the last 8 years, with Q3 2025 value amounting to $8.2 million.

  • Amneal Pharmaceuticals' Share-based Compensation rose 1556.52% to $8.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $31.0 million, marking a year-over-year increase of 1669.3%. This contributed to the annual value of $27.8 million for FY2024, which is 352.7% up from last year.
  • Latest data reveals that Amneal Pharmaceuticals reported Share-based Compensation of $8.2 million as of Q3 2025, which was up 1556.52% from $8.3 million recorded in Q2 2025.
  • Amneal Pharmaceuticals' 5-year Share-based Compensation high stood at $8.3 million for Q2 2025, and its period low was $5.3 million during Q1 2021.
  • In the last 5 years, Amneal Pharmaceuticals' Share-based Compensation had a median value of $7.6 million in 2023 and averaged $7.3 million.
  • As far as peak fluctuations go, Amneal Pharmaceuticals' Share-based Compensation skyrocketed by 5131.33% in 2022, and later crashed by 2371.34% in 2023.
  • Over the past 5 years, Amneal Pharmaceuticals' Share-based Compensation (Quarter) stood at $7.7 million in 2021, then increased by 1.15% to $7.8 million in 2022, then decreased by 23.71% to $6.0 million in 2023, then rose by 20.69% to $7.2 million in 2024, then rose by 13.99% to $8.2 million in 2025.
  • Its Share-based Compensation stands at $8.2 million for Q3 2025, versus $8.3 million for Q2 2025 and $7.3 million for Q1 2025.